Dependence on vaccine-related services and the end of large-scale vaccinations
First written in FY2023. 6 of 8 entries say "Materialised", first in FY2024-Q1. Latest entry: FY2026-H1.
No other company in this theme has enough history to compare yet.
- FY2026-H1MaterialisedAnnual report
「Regarding vaccine sales, we had provided various online reservation systems for COVID-19 vaccinations and other services, but effectively ended providing these services because municipal vaccination programs ended following major changes in the government’s vaccination policy. Accordingly, there were no vaccine sales during the interim consolidated accounting period.」
Following the end of municipal vaccination programs, vaccination-related services were effectively discontinued and no vaccine sales were recorded during the interim consolidated accounting period. - 2026-03-31AchievedBusiness PlanSuggests it is closing out
「Vaccine-related business ended in 2024.」
The company identifies the end of vaccine-related services as a historical fact and indicates that the risk associated with vaccine-related revenue in prior years has ended. - FY2025MaterialisedAnnual report
「In the consolidated fiscal year, vaccine sales declined significantly.」
Vaccine sales fell 99.4%, from ¥163,550 thousand in the fiscal year ended December 2024 to ¥966 thousand in the fiscal year ended December 2025, while their share declined from 12.3% to 0.1%. - FY2025-H1MaterialisedAnnual report
「Regarding vaccine sales, we had provided various online reservation systems for COVID-19 vaccinations and other services, but effectively ended providing these services because municipal vaccination programs ended, except in some areas, following major changes in the government’s vaccination policy.」
Services related to vaccination systems were effectively discontinued, and vaccine sales declined from ¥161,616 thousand, or 23.7%, in the same period of the previous year to ¥966 thousand, or 0.2%. - FY2024MaterialisedAnnual report
「In the consolidated fiscal year, vaccine sales declined significantly.」
Vaccine sales declined significantly, with their share of sales falling from 45.3% in the fiscal year ended December 2023 to 12.3% in the fiscal year ended December 2024. - FY2024-H1MaterialisedAnnual report
「Although we continued providing online reservation systems for vaccinations at some workplace vaccination venues after the large-scale vaccination venues established by the national and prefectural governments had closed, we ended the service at the end of the first quarter.」
Services for some workplace vaccination venues also ended at the end of the first quarter. Revenue from large-scale vaccination and other services declined to ¥640 thousand, or 0.1%, during the interim accounting period. - FY2024-Q1MaterialisedAnnual report
「Although large-scale vaccination venues established by the national and prefectural governments had closed, we provided online reservation systems for vaccinations at some continuing workplace vaccination venues.」
Large-scale vaccination venues established by the national and prefectural governments had closed, leaving only some workplace venues. Revenue from large-scale vaccination and other services was ¥480 thousand, or 0.1%, down from ¥148,754 thousand, or 8.2%, in the fiscal year ended December 2023. - FY2023First statedAnnual report
「As vaccination became widespread among the public and the urgency of vaccination declined in 2023, many of the large-scale vaccination programs described above ended by the end of March 2023. As a result, revenue from large-scale vaccination and other services declined in the fiscal year ended December 2023, as did the proportion of revenue generated through sales partners.」
The company recognized dependence on vaccination-related revenue, particularly large-scale vaccinations, as a risk, and the end of large-scale vaccination programs actually reduced revenue.